AstraZeneca Stock News

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shad...

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.

NEW YORK , Jan. 21, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZenec...

Bloomberg Intelligence analysts identified 50 watchable firms for 2025, focusing on catalysts like new leadership, asset sales, acquisitions, and new products. 14 of 35 dividend-paying companies meet the "safer" criteria with free cash flow yields exceeding dividend yields, inviting closer investor scrutiny. Top ten Bloomberg Dividend Focus stocks for 2025 projected net gains between 11.62% and...

LOS ANGELES , Jan. 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) have opportunity to lead the securities fraud class action lawsuit.

SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating from China. A widening investigation by China regulators into alleged illegal drug imports, data breaches, and potential health insurance fraud has cast a shad...

My thesis initiates coverage of big pharma stock AstraZeneca, with an initial buy rating, agreeing with today's bullish consensus. Positive upside is driven by the diverse portfolio of solutions to meet the clinical demand, and a pipeline of new projects awaiting drug approval. Although the profit margin is weaker than peers, the company is cashflow positive and has positive/stable credit ratings.

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer.